There is no commercial support for this educational activity.
A light smoker presents to his primary care physician with a few weeks’ history of a cough and is ultimately diagnosed with non-small cell lung cancer. Based on a genetic alteration in his tumor, this man may be a candidate for molecularly targeted non-small cell lung cancer therapy.
After participating in this activity, participants should be better able to:
Incorporate a multidisciplinary team approach in diagnosing, staging, and managing patients with NSCLC
Explain the importance of histology and biomarkers in diagnosing and ultimately guiding treatment, particularly with targeted therapies
Evaluate the implications of mutations in the epidermal growth factor receptor (EGFR) and translocations of echinoderm microtubule-associated protein-like 4 gene (EML4)-anaplastic lymphoma kinase (ALK) on the effectiveness of standard chemotherapy compared with targeted therapeutics such as EGFR and ALK inhibitors
Identify the common adverse events with novel therapies and devise solutions to ameliorate these symptoms and patient discomfort
Disclosure of Conflicts of Interest
Colorado Foundation for Medical Care insures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, CFMC identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by CFMC to ensure that all scientific research referred to, reported, or used in a CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CFMC is committed to providing its learners with high-quality CME activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Heather Wakelee, MD Assistant Professor Medicine - Oncology Stanford University School of Medicine Stanford Cancer Institute Stanford, California
Heather Wakelee, MD, receives grant/research support from: Genentech, Lilly, Exelixis, Agennix, Bayer, Clovis Oncology, Novartis, Regeneron, Celgene. Dr. Wakelee will be discussing off-label use of drugs as part of clinical trials.
Planning Committee Disclosures
Lynne Callea, VP, CME Program Management, Suzanne Bujara, Senior Project Editor, and Debra Hughes, Medical Writer of Haymarket Medical Education, have nothing to disclose with regard to commercial support.
Craig Mattingly, MBA, and Lorraine Pickrell of CFMC have nothing to disclose with regard to commercial support.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of the Colorado Foundation for Medical Care, Office of Continuing Education and Haymarket Medical Education. CFMC is accredited by the ACCME to provide continuing medical education for physicians.
Colorado Foundation for Medical Care designates this enduring material internet activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. CFMC and Haymarket Medical Education do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of CFMC and HME. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
To obtain credit, a score of 70% or better is required. This CME is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test survey, and have received your digital copy of your credit certificate. Your online certificate will be saved on myCME.com within your Profile/Exam History, which you can then access at any time.